Covered recipient · General Payments record
FARNOUSH KARIMPOUR
Nursing Service Providers Licensed Practical Nurse
General Payments · PY2021–2024
$771.93
- Reported across 30 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $573.04 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $311.86 | 9 |
| GlaxoSmithKline, LLC. | $110.71 | 1 |
| Acerta Pharma LLC | $41.73 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $34.04 | 1 |
| Verrica Pharmaceuticals Inc. | $20.03 | 1 |
| Merck Sharp & Dohme Corporation | $19.64 | 1 |
| Phathom Pharmaceuticals, Inc. | $17.98 | 1 |
| Lilly USA, LLC | $17.05 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $81.89 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107438173 | CMS |
| ABBVIE INC. | $11.16 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107438175 | CMS |
| ABBVIE INC. | $7.89 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107438177 | CMS |
| ABBVIE INC. | $20.30 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107438179 | CMS |
| ABBVIE INC. | $21.62 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107438181 | CMS |
| ABBVIE INC. | $124.41 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107438183 | CMS |
| ABBVIE INC. | $12.48 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107438185 | CMS |
| ABBVIE INC. | $14.93 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107438187 | CMS |
| ABBVIE INC. | $17.18 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107438189 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.58 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104419935 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.15 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104545174 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $34.04 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086351788 | CMS |
| GlaxoSmithKline, LLC. | $110.71 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116384196 | CMS |
| Lilly USA, LLC | $17.05 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135667646 | CMS |
| Merck Sharp & Dohme LLC | $19.64 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141937173 | CMS |
| Phathom Pharmaceuticals, Inc. | $17.98 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151178908 | CMS |
| Verrica Pharmaceuticals Inc. | $20.03 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118393138 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.